March 23, 2017 08:13 AM EDT

Did President Trump just jump the shark on drug prices?

John Carroll

Editor & Founder

President Donald Trump has vowed repeatedly to slash drug prices, frequently trashing greedy pharma companies and their pricing policies. And in remarks he made …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Did President Trump just jump the shark on drug prices?

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Did Pres­i­dent Trump just jump the shark on drug prices?

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Did President Trump just jump the shark on drug prices?

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Neumora's major depression drug flunks first of three Phase 3 trials

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes